ES2982022T3 - Formulaciones tópicas de detomidina - Google Patents

Formulaciones tópicas de detomidina Download PDF

Info

Publication number
ES2982022T3
ES2982022T3 ES18701853T ES18701853T ES2982022T3 ES 2982022 T3 ES2982022 T3 ES 2982022T3 ES 18701853 T ES18701853 T ES 18701853T ES 18701853 T ES18701853 T ES 18701853T ES 2982022 T3 ES2982022 T3 ES 2982022T3
Authority
ES
Spain
Prior art keywords
detomidine
formulation
salt
topical
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18701853T
Other languages
English (en)
Spanish (es)
Inventor
Omer Tsipori
Mark Zamansky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clexio Bioscience Ltd
Original Assignee
Clexio Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clexio Bioscience Ltd filed Critical Clexio Bioscience Ltd
Application granted granted Critical
Publication of ES2982022T3 publication Critical patent/ES2982022T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES18701853T 2017-01-06 2018-01-05 Formulaciones tópicas de detomidina Active ES2982022T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762443174P 2017-01-06 2017-01-06
PCT/US2018/012579 WO2018129313A1 (en) 2017-01-06 2018-01-05 Topical detomidine formulations

Publications (1)

Publication Number Publication Date
ES2982022T3 true ES2982022T3 (es) 2024-10-14

Family

ID=61054537

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18701853T Active ES2982022T3 (es) 2017-01-06 2018-01-05 Formulaciones tópicas de detomidina

Country Status (15)

Country Link
US (2) US20190343805A1 (enExample)
EP (1) EP3565526B1 (enExample)
JP (1) JP2020505322A (enExample)
KR (1) KR20190110561A (enExample)
CN (1) CN110114059A (enExample)
AU (1) AU2018205217B2 (enExample)
BR (1) BR112019011961A2 (enExample)
CA (1) CA3049389A1 (enExample)
DK (1) DK3565526T3 (enExample)
ES (1) ES2982022T3 (enExample)
HU (1) HUE068070T2 (enExample)
IL (1) IL266448B2 (enExample)
MX (1) MX382949B (enExample)
PL (1) PL3565526T3 (enExample)
WO (1) WO2018129313A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020012415A2 (en) * 2018-07-11 2020-01-16 Clexio Biosciences Ltd. Topical detomidine formulations
WO2020016827A1 (en) * 2018-07-18 2020-01-23 Clexio Biosciences Ltd. Purified crystalline detomidine hydrochloride monohydrate, anhydrate and free base with low amounts of iso-detomidine and other impurities by recrystallisation in water
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido
US20220211672A1 (en) 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10256774A1 (de) * 2002-12-05 2004-06-24 Lts Lohmann Therapie-Systeme Ag Transmucosale und transdermale Arzneimittel mit verbesserter Wirkstoffresorption
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
WO2011127586A1 (en) * 2010-04-15 2011-10-20 The Royal Institution For The Advancement Of Learning / Mcgill University Topical treatments for pain
WO2013076160A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
EP2803668A1 (en) * 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CA2921221A1 (en) * 2013-08-14 2015-02-19 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for controlling pain
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain

Also Published As

Publication number Publication date
WO2018129313A1 (en) 2018-07-12
IL266448A (en) 2019-06-30
MX382949B (es) 2025-03-13
JP2020505322A (ja) 2020-02-20
AU2018205217B2 (en) 2023-11-09
US20230172909A1 (en) 2023-06-08
IL266448B1 (en) 2023-07-01
EP3565526B1 (en) 2024-04-17
MX2019008115A (es) 2019-10-24
CN110114059A (zh) 2019-08-09
US20190343805A1 (en) 2019-11-14
EP3565526A1 (en) 2019-11-13
CA3049389A1 (en) 2018-07-12
IL266448B2 (en) 2023-11-01
PL3565526T3 (pl) 2024-09-09
BR112019011961A2 (pt) 2019-11-05
AU2018205217A1 (en) 2019-05-23
KR20190110561A (ko) 2019-09-30
DK3565526T3 (en) 2024-05-13
HUE068070T2 (hu) 2024-12-28

Similar Documents

Publication Publication Date Title
US20230172909A1 (en) Topical detomidine formulations
US8609722B2 (en) Anesthetic composition for topical administration comprising lidocaine, prilocaine and tetracaine
ES2445443T3 (es) Solución tópica no acuosa de diclofenaco y proceso para la preparación de la misma
CA2466536C (en) Transdermal transport of compounds
US20180296506A1 (en) High concentration local anesthetic formulations
PL207845B1 (pl) Spray donosowy do dostarczania kompozycji farmaceutycznej zawierającej fentanyl i zastosowanie soli fentanylu do wytwarzania środka leczniczego
US20210267998A1 (en) Methods and compositions for treatment of peripheral neuropathies
ES2585253T3 (es) Composiciones para prevenir la pérdida de cabello o para estimular el crecimiento del cabello
Macedo et al. Microneedles enhance topical delivery of 15-deoxy-Δ12, 14-prostaglandin J2 and reduce nociception in temporomandibular joint of rats
BRPI0609929A2 (pt) método transdérmico e esparadrapo para náusea
JP7534795B2 (ja) そう痒症を治療する方法
Mathews et al. Management of pain using transdermal patches-a review
EA007351B1 (ru) Фармацевтическая композиция для чрескожной доставки физиологически активных агентов
CN110402142A (zh) 含局麻药的酸性乳液组合物
US20110218218A1 (en) Formulations Of Indanylamines And The Use Thereof As Local Anesthetics And As Medication For Chronic Pain
US20220305076A1 (en) Topical cyclosporine for treating psoriasis and other ailments
JP6016085B2 (ja) 抗真菌外用組成物及び抗真菌外用組成物の適用方法
BR112021003746A2 (pt) sistema de distribuição transdermal de fármacos
Thacker et al. EFFECT OF ADDING FENTANYL TO LOCAL ANAESTHETICS IN BRACHIAL PLEXUS BLOCK ON THE ONSET AND DURATION OF ANESTHESIA AND POSTOPERATIVE ANALGESIA